Male DNA in Female Donor Apheresis and CD34-Enriched Products

Kristina M. Adams1,2, Nathalie C. Lambert1, Shelly Heimfeld1, Tracy S. Tylee3, Jennifer M. Pang1, Timothy D. Erickson1, and J. Lee Nelson1,4

From the Division of Clinical Research1, Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Obstetrics & Gynecology2, School of Medicine3, and Division of Rheumatology4, University of Washington, Seattle, Washington, U.S.A

Running Head: Male DNA in Female Donor Apheresis Products
Scientific Section Heading: Transplantation

Supported by grants HD01264, AI41721, AR48084, CA15704, and CA18029 from the National Institutes of Health.

Corresponding author: Kristina Adams, MD, Fred Hutchinson Cancer Research Center, Human Immunogenetics Program
1100 Fairview Ave. N., D2-100, PO Box 19024
Seattle, WA 98109-19024
Phone: 206-667-7002
Fax: 206-667-5255
Email: adamsk@u.washington.edu

Total Text Word Count: 1,200
Abstract Only: 148
Abstract

Increased risk of graft-versus-host-disease (GVHD) has been described in hematopoietic stem cell transplantation recipients when the donor is a parous woman. Cells from prior pregnancies are now known to persist in women and could contribute to GVHD. We asked whether male DNA (presumed fetal microchimerism) is present in apheresis products of female donors. A total of 50 samples were studied employing Real-Time quantitative PCR for the Y-chromosome specific sequence DYS14. Among 29 growth factor mobilized peripheral blood mononuclear cell products (G-PBMC), 34% were positive for male DNA. Quantitative results, expressed as DNA genome equivalent of male cells per million host cells (gEq/mil), ranged from 0 to 35 gEq/mil. Among 21 CD34-enriched cell fractions, 48% were positive with a range of 0 to 357 gEq/mil. In summary, male DNA was frequently detected in G-PBMC and CD34-enriched products from female donors. Whether fetal microchimerism contributes to GVHD merits further investigation.
Introduction

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of mortality and morbidity. HLA incompatibility is the strongest risk factor for GVHD, but other factors including donor parity are thought to play a role.\textsuperscript{1-4} The reason(s) for increased risk of GVHD when the donor is a parous woman is unknown. Flowers et al suggested that allosensitization of maternal T-cells to fetal minor histocompatibility antigens during pregnancy could prime cells to similar antigens in a transplant recipient.\textsuperscript{1} However, the discovery that fetal cells persist in the circulation of parous women decades after childbirth raises the question whether non-HLA-matched fetal cells are present in apheresis products and could contribute to GVHD. Fetal microchimerism (FMc) refers to low levels of fetal cells harbored by the mother, which persist at least 38 years postpartum.\textsuperscript{5,6} FMc has also been described in cellular subsets including CD34\textsuperscript{+}CD38\textsuperscript{+}, CD3 (including CD4 and CD8), CD19, CD14, and CD56/16 subsets.\textsuperscript{6,7} Our objective was to determine whether male DNA (probable FMc) is present in apheresis products from female donors. Growth factor mobilized peripheral blood mononuclear cells (G-PBMC) and CD34-enriched apheresis products of female donors were tested using real-time quantitative PCR (QPCR) for DYS14, a Y-chromosome specific sequence.

Methods:

Study design and subjects. A total of 50 G-PBMC and CD34-enriched apheresis products from 46 women collected between March 2001 and April 2003 at the Fred Hutchinson Cancer Research Center (FHCRC, Seattle, WA) were studied. The FHCRC Institutional Review Board approved the study. Samples from female donors were unidentified and obtained randomly from the Cellular Therapy Laboratory on the day of apheresis (G-PBMC, n=25) or from a cryopreserved research repository (CD34-enriched, n=12). Pregnancy and transfusion history in these women was unknown. Additional G-PBMC apheresis products were obtained from women with scleroderma (systemic
sclerosis; SSc) undergoing autologous transplant (G-PBMC, n=4; CD34-enriched, n=9). For these subjects, pregnancy and transfusion history was known.

*Peripheral blood mononuclear cell mobilization (PBMC) and CD34-enrichment.* PBMC mobilization was performed using either recombinant granulocyte colony-stimulating factor (G-CSF) alone or intermediate-dose chemotherapy followed by G-CSF. Donors underwent a 16 to 20 liter leukapheresis using a continuous-flow blood separator (Cobe Spectra, Cobe Laboratories, Lakewood, CO). CD34-enrichment was performed using the Baxter 300 Isolex System (Baxter, Inc, Irvine, CA) or Cellpro Ceprate System (Cellpro, Seattle, WA).

*Quantitation of male DNA by real-time QPCR.* Genomic DNA was extracted using Promega Wizard Purification Kits (Promega, Madison, WI) according to manufacturer’s instructions. QPCR methods and β-globin primers have previously been described. We previously reported QPCR using DYS14 as a Y-chromosome specific target. Twelve aliquots of DNA were tested from each donor. Two additional DNA aliquots were amplified with β-globin primers for quantitation of host DNA. Standard curves for β-globin and DYS14 were run simultaneously and the quantitation threshold was set where amplifications were consistently in a linear range (Figure 1). For ease of expression, DNA quantities were reported as the DNA genome equivalent number of male cells per million host cells (gEq/mil) using a conversion factor of 6.6 pg of DNA per cell. The male gEq for each sample was calculated by summing quantities of male DNA over aliquots and dividing by the total host gEq assayed. Assuming that the presence of male DNA in female donor apheresis products follows a Poisson process, the result represents the maximum likelihood estimate of the Poisson mean rate for each subject. Testing 10,000 gEq per aliquot (approximately 120,000 total gEq) was experimentally determined to be optimal for the QPCR assay (data not shown). Excessive host DNA is inhibitory for QPCR amplifications and testing too little host DNA decreases quantitation sensitivity. An acceptable range of total host DNA tested per subject was considered to be 50,000 - 240,000 gEq.

Each PCR reaction contained 5 µl DNA, 5 µl 10X platinum buffer, 300 nM of each amplification primer, 100 nM dual-labeled probe, 200 nM of each deoxynucleoside triphosphate (dNTP), 3.5 mM MgCl₂, 1.5 U platinum *Taq* (Gibco BRL, Burlington, ON,
Canada), and 60 nM of Rox reference dye (Synthegen, Houston, TX) for a total reaction volume of 50 µl. Initial incubation was at 50°C for 2 minutes, followed by 95°C for 10 minutes, 45 cycles of 95°C for 15 seconds, and 60°C for 1 minute. A Perkin-Elmer Applied Biosystems 7000 sequence detector collected the amplification data; data was analyzed using Sequence Detection System software (PE Applied Biosystems, Foster City, CA).

Figure 1. Representative QPCR amplification plot of male DNA in G-PBMC of a female donor.

The x-axis represents the number of cycles of a PCR reaction and the y-axis is fluorescence intensity over background. With increasing cycle number, smaller DNA quantities amplify. Each sample is tested for β-globin (measure of total DNA) and DYS14 (measure of male DNA) with quantitative results assessed by the intersection of the amplification plots with the threshold.

Results and Discussion:

Overall, we found male DNA in 34% of G-PBMC samples and 48% of CD34-selected samples. The mean number of gEq assayed per patient was 121,717 (range
59,640 to 222,600). The quantitative range of male DNA detected in G-PBMC was 0-35 gEq/mil and in CD34-enriched samples was 0-357 gEq/mil (Figure 2). The highest level of male DNA detected was in the CD34-enriched apheresis product of a woman with SSc (357 male gEq/mil). She gave birth to three sons and had no history of blood transfusion prior to autologous transplant. No male cells were detected in any of the other 8 women with SSc, including three who had previously given birth to sons. Given the low frequency of events that we are detecting and the finite amount of DNA tested, our results may be an underestimate of the true prevalence of male DNA in female donor apheresis and CD34-enriched products.

**Figure 2. Male DNA in G-PBMC and CD34-Enriched Apheresis Products of Female Donors.**

Each symbol represents results for one of a total of 50 apheresis products tested, deriving from 46 women. Four women with SSc had both G-PBMC and CD34-enriched products tested (all samples negative.)
We present data that male DNA (probable FMc) is not uncommon in G-PBMC and CD34-enriched apheresis products from female donors. The male DNA most likely resulted from a prior pregnancy, although in some subjects it could derive from a blood transfusion as we lacked this history in unidentified subjects. However, the highest level of male DNA was presumably of fetal origin, as the woman had no blood transfusions and had given birth to 3 sons. Thus, our results suggest donor FMc is present both in G-PBMC and CD34-enriched apheresis products, although the FMc in these products could derive from a variety of cell lineages. Estimating from the lowest quantity of male DNA detected (1 gEq/mil), this would represent approximately 10,000 – 40,000 male cells infused during a typical HSCT using G-PBMC.11

Although immunoregulatory mechanisms must exist to allow tolerance of microchimeric cells in the donor, transplantation into an immunocompromised recipient could change their propensity to cause disease. Maternal cells, for example, may cause GVHD when they engraft in children with immunodeficiency.12 Either HLA-disparate fetal T-cells transferred in apheresis products or the T-cell progeny of engrafted fetal stem cells could initiate GVHD. Alternatively, fetal stem cells could give rise to antigen-presenting cells, which could activate donor and/or fetal T-cells.

In addition to FMc, other sources of chimerism may be transferred during HSCT. Non-irradiated blood transfusions can result in persistent microchimerism or lead to transfusion-associated GVHD.13,14 Cells from the mother traffic into the fetus during pregnancy and persist into adult life.15 Chimerism may also develop with cell transfer between twins in utero.5 These sources of chimerism could contribute to GVHD with male or nulligravid female donors. To our knowledge, no prior studies have addressed the hypothesis that donor FMc is transferred during HSCT or may be implicated in GVHD. The impact of transplanting a small population of non-HLA-matched cells on the development of GVHD is unknown and merits further study.
References


Male DNA in female donor apheresis and CD34-enriched products

Kristina M Adams, Nathalie C Lambert, Shelly Heimfeld, Tracy S Tylee, Jennifer M Pang, Timothy D Erickson and J L Nelson

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.